Table of Contents 1 Key Insights 2 Mucopolysaccharidosis I Market Overview at a Glance 2.1 Market Share (%) Distribution of Mucopolysaccharidosis I in 2018 2.2 Market Share (%) Distribution of Mucopolysaccharidosis I in 2028 3 Mucopolysaccharidosis I: Disease Background and Overview 3.1 Introduction 3.2 Symptoms 3.3 Etiology 3.4 Risk Factor 3.5 Pathophysiology 3.6 Diagnosis 3.7 Treatment 4 Epidemiology and Patient Population 4.1. Key Findings 4.2. Total Prevalent/ Incident Patient Population of Mucopolysaccharidosis I in 7MM 4.3. Total Prevalent Patient Population of Mucopolysaccharidosis I in 7MM – By Countries 5 Epidemiology of Mucopolysaccharidosis I by Countries (2016-2028) 5.1 United States- Epidemiology (2016-2028) 5.1.1 Assumptions and Rationale 5.1.2 Prevalent/Incident Cases of Mucopolysaccharidosis I in the United States 5.1.3 Sub-Type Specific cases of Mucopolysaccharidosis I in the United States 5.1.4 Sex- Specific Cases of Mucopolysaccharidosis I in the United States 5.1.5 Diagnosed Cases of Mucopolysaccharidosis I in the United States 5.1.6 Treatable Cases of Mucopolysaccharidosis I in the United States 5.2 EU5 Countries 5.2.1 Germany 5.2.1.1 Assumptions and Rationale 5.2.1.2 Prevalent/Incident Cases of the of Mucopolysaccharidosis I in the Germany 5.2.1.3 Sub-Type Specific cases of Mucopolysaccharidosis I in the Germany 5.2.1.4 Sex- Specific Cases of the Mucopolysaccharidosis I in the Germany 5.2.1.5 Diagnosed Cases of the Mucopolysaccharidosis I in the Germany 5.2.1.6 Treatable Cases of the Mucopolysaccharidosis I 5.2.2 France 5.2.2.1 Assumptions and Rationale 5.2.2.2 Prevalent/Incident Cases of the of Mucopolysaccharidosis I in the France 5.2.2.3 Sub-Type Specific cases of Mucopolysaccharidosis I in the France 5.2.2.4 Sex- Specific Cases of the Mucopolysaccharidosis I in the France 5.2.2.5 Diagnosed Cases of the Mucopolysaccharidosis I in the France 5.2.2.6 Treatable Cases of the Mucopolysaccharidosis I 5.2.3 Italy 5.2.3.1 Assumptions and Rationale 5.2.3.2 Prevalent/Incident Cases of the of Mucopolysaccharidosis I in the Italy 5.2.3.3 Sub-Type Specific cases of Mucopolysaccharidosis I in the Italy 5.2.3.4 Sex- Specific Cases of the Mucopolysaccharidosis I in the Italy 5.2.3.5 Diagnosed Cases of the Mucopolysaccharidosis I in the Italy 5.2.3.6 Treatable Cases of the Mucopolysaccharidosis I 5.2.4 Spain 5.2.4.1 Assumptions and Rationale 5.2.4.2 Prevalent/Incident Cases of the of Mucopolysaccharidosis I in the Spain 5.2.4.3 Sub-Type Specific cases of Mucopolysaccharidosis I in the Spain 5.2.4.4 Sex- Specific Cases of the Mucopolysaccharidosis I in the Spain 5.2.4.5 Diagnosed Cases of the Mucopolysaccharidosis I in the Spain 5.2.4.6 Treatable Cases of the Mucopolysaccharidosis I 5.2.5 United Kingdom 5.2.5.1 Assumptions and Rationale 5.2.5.2 Prevalent/Incident Cases of the of Mucopolysaccharidosis I in the United Kingdom 5.2.5.3 Sub-Type Specific cases of Mucopolysaccharidosis I in the United Kingdom 5.2.5.4 Sex- Specific Cases of the Mucopolysaccharidosis I in the United Kingdom 5.2.5.5 Diagnosed Cases of the Mucopolysaccharidosis I in the United Kingdom 5.2.5.6 Treatable Cases of the Mucopolysaccharidosis I 5.3 Japan 5.3.1 Assumptions and Rationale 5.3.2 Prevalent/Incident Cases of the of Mucopolysaccharidosis I in the Japan 5.3.3 Sub-Type Specific cases of Mucopolysaccharidosis I in the Japan 5.3.4 Sex- Specific Cases of the Mucopolysaccharidosis I in the Japan 5.3.5 Diagnosed Cases of the Mucopolysaccharidosis I in the Japan 5.3.6 Treatable Cases of the Mucopolysaccharidosis I 6 Current Treatment & Medical practices 6.1 Treatment Algorithm 6.2 Treatment Guidelines 7 Unmet Needs 8 Marketed Product 8.1 Drug A: Company 1 8.1.1 Drug Description 8.1.2 Mechanism of Action 8.1.3 Clinical Trials Details 8.1.4 Advantages & Disadvantages 8.1.5 Safety and Efficacy 8.1.6 Product Profile 8.2 Drug B: Company 2 8.2.1 Drug Description 8.2.2 Mechanism of Action 8.2.3 Clinical Trials Details 8.2.4 Advantages & Disadvantages 8.2.5 Safety and Efficacy 8.2.6 Product Profile 8.3 Drug C: Company 3 8.3.1 Drug Description 8.3.2 Mechanism of Action 8.3.3 Clinical Trials Details 8.3.4 Advantages & Disadvantages 8.3.5 Safety and Efficacy 8.3.6 Product Profile 8.4 Drug D: Company 4 8.4.1 Drug Description 8.4.2 Mechanism of Action 8.4.3 Clinical Trials Details 8.4.4 Advantages & Disadvantages 8.4.5 Safety and Efficacy 8.4.6 Product Profile 8.5 Drug E: Company 5 8.5.1 Drug Description 8.5.2 Mechanism of Action 8.5.3 Clinical Trials Details 8.5.4 Advantages & Disadvantages 8.5.5 Safety and Efficacy 8.5.6 Product Profile 8.6 : Company 6 8.6.1 Drug Description 8.6.2 Mechanism of Action 8.6.3 Clinical Trials Details 8.6.4 Advantages & Disadvantages 8.6.5 Safety and Efficacy 8.6.6 Product Profile 8.7 : Company 7 8.7.1 Drug Description 8.7.2 Mechanism of Action 8.7.3 Clinical Trials Details 8.7.4 Advantages & Disadvantages 8.7.5 Safety and Efficacy 8.7.6 Product Profile 8.8 : Company 8 8.8.1 Drug Description 8.8.2 Mechanism of Action 8.8.3 Clinical Trials Details 8.8.4 Advantages & Disadvantages 8.8.5 Safety and Efficacy 8.8.6 Product Profile 9 Emerging Drugs 9.1 Key Cross Competition 9.2 Emerging company 9.2.1 Emerging Drug A: Company 16 9.2.1.1 Other Development Activities 9.2.1.2 Clinical Development 9.2.1.3 Clinical Trials Information 9.2.1.4 Safety and Efficacy 9.2.1.5 Advantages and Disadvantages 9.2.1.6 Product Profile 9.2.2 Emerging Drug B: Company 17 9.2.2.1 Other Development Activities 9.2.2.2 Clinical Development 9.2.2.3 Clinical Trials Information 9.2.2.4 Safety and Efficacy 9.2.2.5 Advantages and Disadvantages 9.2.2.6 Product Profile 9.2.3 Emerging Drug C: Company 18 9.2.3.1 Other Development Activities 9.2.3.2 Clinical Development 9.2.3.3 Clinical Trials Information 9.2.3.4 Safety and Efficacy 9.2.3.5 Advantages and Disadvantages 9.2.3.6 Product Profile 9.2.4 Emerging Drug D: Company 19 9.2.4.1 Other Development Activities 9.2.4.2 Clinical Development 9.2.4.3 Clinical Trials Information 9.2.4.4 Safety and Efficacy 9.2.4.5 Advantages and Disadvantages 9.2.4.6 Product Profile 9.2.5 Emerging Drug E: Company 20 9.2.5.1 Other Development Activities 9.2.5.2 Clinical Development 9.2.5.3 Clinical Trials Information 9.2.5.4 Safety and Efficacy 9.2.5.5 Advantages and Disadvantages 9.2.5.6 Product Profile 10 7MM Market Analysis 10.1 7MM Market Size of Mucopolysaccharidosis I 10.2 7MM Percentage Share of Drugs Marketed for Mucopolysaccharidosis I 10.3 7MM Market Sales of Mucopolysaccharidosis I by Products 11 The United States Market Outlook 11.1 Market Size of Mucopolysaccharidosis I in United States 11.2 Percentage Share of Drugs Marketed for Mucopolysaccharidosis I in United States 11.3 Market Sales of Mucopolysaccharidosis I by Products in United States 11.4 Analysis of Upcoming Therapies and Impact on the Market 12 EU5 Countries Market Outlook 12.1 Market Size of Mucopolysaccharidosis I in EU5 12.2 Market Size of Mucopolysaccharidosis I in Germany 12.2.1 Market Size of Mucopolysaccharidosis I in Germany 12.2.2 Percentage Share of Drugs Marketed for Mucopolysaccharidosis I in Germany 12.2.3 Market Sales of Mucopolysaccharidosis I by Products in Germany 12.2.4 Analysis of Upcoming Therapies and Impact on the Market 12.3 Market Size of Mucopolysaccharidosis I in France 12.3.1 Market Size of Mucopolysaccharidosis I in France 12.3.2 Percentage Share of Drugs Marketed for Mucopolysaccharidosis I in France 12.3.3 Market Sales of Mucopolysaccharidosis I by Products in France 12.3.4 Analysis of Upcoming Therapies and Impact on the Market 12.4 Market Size of Mucopolysaccharidosis I in Italy 12.4.1 Market Size of Mucopolysaccharidosis I in Italy 12.4.2 Percentage Share of Drugs Marketed for Mucopolysaccharidosis I in Italy 12.4.3 Market Sales of Mucopolysaccharidosis I by Products in Italy 12.4.4 Analysis of Upcoming Therapies and Impact on the Market 12.5 Market Size of Mucopolysaccharidosis I in Spain 12.5.1 Market Size of Mucopolysaccharidosis I in Spain 12.5.2 Percentage Share of Drugs Marketed for Mucopolysaccharidosis I in Spain 12.5.3 Market Sales of Mucopolysaccharidosis I by Products in Spain 12.5.4 Analysis of Upcoming Therapies and Impact on the Market 12.6 Market Size of Mucopolysaccharidosis I in United Kingdom 12.6.1 Market Size of Mucopolysaccharidosis I in United Kingdom 12.6.2 Percentage Share of Drugs Marketed for Mucopolysaccharidosis I in United Kingdom 12.6.3 Market Sales of Mucopolysaccharidosis I by Products in United Kingdom 12.6.4 Analysis of Upcoming Therapies and Impact on the Market 13 The Japan Market Outlook 13.1 Market Size of Mucopolysaccharidosis I in Japan 13.2 Percentage Share of Drugs Marketed for Mucopolysaccharidosis I in Japan 13.3 Market Sales of Mucopolysaccharidosis I by Products in Japan 13.4 Analysis of Upcoming Therapies and Impact on the Market 14 Cost Analysis of Mucopolysaccharidosis I 15 Generic Competition in Mucopolysaccharidosis I Market 16 Market Drivers 17 Market Barriers 18 Report Methodology 18.1 Methodology/Research Approach 18.2 Data Source 18.2.1 Secondary Sources 18.2.2 Primary Sources

List of Tables Table Total Prevalent/Incident Cases of the Mucopolysaccharidosis I in 7MM (2016-2028) Table Total Prevalent/Incident Cases of the Mucopolysaccharidosis I in 7MM by Countries (2016-2028) Table Prevalent/Incident Cases of the Mucopolysaccharidosis I in United States (2016-2028) Table Sub-Type Specific cases of Mucopolysaccharidosis I in the United States (2016-2028) Table Sex- Specific Cases of Mucopolysaccharidosis I in the United States (2016-2028) Table Diagnosed Cases of the Mucopolysaccharidosis I in United States (2016-2028) Table Treatable Cases of the Mucopolysaccharidosis I in United States (2016-2028) Table Prevalent/Incident Cases of the Mucopolysaccharidosis I in Germany (2016-2028) Table Sub-Type Specific cases of Mucopolysaccharidosis I in the Germany (2016-2028) Table Sex- Specific Cases of Mucopolysaccharidosis I in the Germany (2016-2028) Table Diagnosed Cases of the Mucopolysaccharidosis I in Germany (2016-2028) Table Treatable Cases of the Mucopolysaccharidosis I in Germany (2016-2028) Table Prevalent/Incident Cases of the Mucopolysaccharidosis I in France (2016-2028) Table Sub-Type Specific cases of Mucopolysaccharidosis I in the France (2016-2028) Table Sex- Specific Cases of Mucopolysaccharidosis I in the France (2016-2028) Table Diagnosed Cases of the Mucopolysaccharidosis I in France (2016-2028) Table Treatable Cases of the Mucopolysaccharidosis I in France (2016-2028) Table Prevalent/Incident Cases of the Mucopolysaccharidosis I in Italy (2016-2028) Table Sub-Type Specific cases of Mucopolysaccharidosis I in the Italy (2016-2028) Table Sex- Specific Cases of Mucopolysaccharidosis I in the Italy (2016-2028) Table Diagnosed Cases of the Mucopolysaccharidosis I in Italy (2016-2028) Table Treatable Cases of the Mucopolysaccharidosis I in Italy (2016-2028) Table Prevalent/Incident Cases of the Mucopolysaccharidosis I in Spain (2016-2028) Table Sub-Type Specific cases of Mucopolysaccharidosis I in the Spain (2016-2028) Table Sex- Specific Cases of Mucopolysaccharidosis I in the Spain (2016-2028) Table Diagnosed Cases of the Mucopolysaccharidosis I in Spain (2016-2028) Table Treatable Cases of the Mucopolysaccharidosis I in Spain (2016-2028) Table Prevalent/Incident Cases of the Mucopolysaccharidosis I in United Kingdom (2016-2028) Table Sub-Type Specific cases of Mucopolysaccharidosis I in the United Kingdom (2016-2028) Table Sex- Specific Cases of Mucopolysaccharidosis I in the United Kingdom (2016-2028) Table Diagnosed Cases of the Mucopolysaccharidosis I in United Kingdom (2016-2028) Table Treatable Cases of the Mucopolysaccharidosis I in United Kingdom (2016-2028) Table Prevalent/Incident Cases of the Mucopolysaccharidosis I in Japan (2016-2028) Table Sub-Type Specific cases of Mucopolysaccharidosis I in the Japan (2016-2028) Table Sex- Specific Cases of Mucopolysaccharidosis I in the Japan (2016-2028) Table Diagnosed Cases of the Mucopolysaccharidosis I in Japan (2016-2028) Table Treatable Cases of the Mucopolysaccharidosis I in Japan (2016-2028) Table Drug Description Table Mechanism of Action Table Clinical Trials Details Table Advantages & Disadvantages Table Safety and Efficacy Table Product Profile Table Drug Description Table Mechanism of Action Table Clinical Trials Details Table Advantages & Disadvantages Table Safety and Efficacy Table Product Profile Table Drug Description Table Mechanism of Action Table Clinical Trials Details Table Advantages & Disadvantages Table Safety and Efficacy Table Product Profile Table Drug Description Table Mechanism of Action Table Clinical Trials Details Table Advantages & Disadvantages Table Safety and Efficacy Table Product Profile Table Drug Description Table Mechanism of Action Table Clinical Trials Details Table Advantages & Disadvantages Table Safety and Efficacy Table Product Profile Table Drug Description Table Mechanism of Action Table Clinical Trials Details Table Advantages & Disadvantages Table Safety and Efficacy Table Product Profile Table Drug Description Table Mechanism of Action Table Clinical Trials Details Table Advantages & Disadvantages Table Safety and Efficacy Table Product Profile Table Drug Description Table Mechanism of Action Table Clinical Trials Details Table Advantages & Disadvantages Table Safety and Efficacy Table Product Profile Table Comparison of emerging drugs (Immunomodulators) under development Table Comparison of emerging drugs (other classes) under development Table Safety and Efficacy Table Product Advantages and Advantages Table Clinical Trial Description, 2018 Table Safety and Efficacy Table Product Advantages and Advantages Table Clinical Trial Description, 2018 Table Safety and Efficacy Table Product Advantages and Advantages Table Clinical Trial Description, 2018 Table Safety and Efficacy Table Product Advantages and Advantages Table Clinical Trial Description, 2018 Table Safety and Efficacy Table Product Advantages and Advantages Table Clinical Trial Description, 2018 Table7MM- Market Size of Mucopolysaccharidosis I in USD MM (2016-2028) Table 7MM- Market Share Mucopolysaccharidosis I by Therapies in USD MM (2016-2028) Table 7MM- Market Sales of Mucopolysaccharidosis I by Therapies in USD MM (2016-2028) Table US Market Size of Mucopolysaccharidosis I in USD, Million (2016-2028) Table United States-Market Share Mucopolysaccharidosis I by Therapies in USD MM (2016-2028) Table United States-Market Sales of Mucopolysaccharidosis I by Therapies in USD MM (2016-2028) Table EU5 Market Size of Mucopolysaccharidosis I (MS) in USD, Million (2016-2028) Table Germany Market Size of Mucopolysaccharidosis I in USD, Million (2016-2028) Table Germany -Market Share Mucopolysaccharidosis I by Therapies in USD MM (2016-2028) Table Germany -Market Sales of Mucopolysaccharidosis I by Therapies in USD MM (2016-2028) Table France Market Size of Mucopolysaccharidosis I in USD, Million (2016-2028) Table France -Market Share Mucopolysaccharidosis I by Therapies in USD MM (2016-2028) Table France -Market Sales of Mucopolysaccharidosis I by Therapies in USD MM (2016-2028) Table Italy Market Size of Mucopolysaccharidosis I in USD, Million (2016-2028) Table Italy -Market Share Mucopolysaccharidosis I by Therapies in USD MM (2016-2028) Table Italy -Market Sales of Mucopolysaccharidosis I by Therapies in USD MM (2016-2028) Table Spain Market Size of Mucopolysaccharidosis I in USD, Million (2016-2028) Table Spain -Market Share Mucopolysaccharidosis I by Therapies in USD MM (2016-2028) Table Spain -Market Sales of Mucopolysaccharidosis I by Therapies in USD MM (2016-2028) Table United Kingdom Market Size of Mucopolysaccharidosis I in USD, Million (2016-2028) Table United Kingdom -Market Share Mucopolysaccharidosis I by Therapies in USD MM (2016-2028) Table United Kingdom -Market Sales of Mucopolysaccharidosis I by Therapies in USD MM (2016-2028) Table Japan Market Size of Mucopolysaccharidosis I in USD, Million (2016-2028) Table Japan -Market Share Mucopolysaccharidosis I by Therapies in USD MM (2016-2028) Table Japan -Market Sales of Mucopolysaccharidosis I by Therapies in USD MM (2016-2028) Table Market Drivers of Mucopolysaccharidosis I Table Market Barriers of Mucopolysaccharidosis I ???